Thoracic surgeon Daniela Molena leads clinical trials to improve outcomes for people with esophageal cancers.
At any time Memorial Sloan Kettering Cancer Center is conducting hundreds of clinical trials to improve care for many types of cancer. Use the tool below to browse our clinical trials that are currently enrolling new patients. Each listing explains the purpose of the trial, the trial’s eligibility criteria, and how to get more information.
The list below includes clinical trials for adult cancers. Please visit our pediatric cancer care section to find a pediatric clinical trial.
This study will compare the effects of different amounts of aerobic exercise on heart and lung (cardiorespiratory) fitness in post-menopausal women who completed treatment for early-stage breast cancer. Researchers will study the effects of different exercise programs on oxygen use, heart pumping ability, lung function, and blood vessel health. Participants will be randomly assigned to one of four groups:
Researchers want to find the highest dose of ERAS-0015 that can be given safely in people with advanced solid tumors. The people in this study have cancer that has metastasized (spread) and has a mutation in the RAS gene.
Researchers want to find the best dose of LY4066434 when given alone and with other drugs to treat solid tumors. The people in this study have cancer that has spread (advanced) or cannot be removed with surgery (inoperable). These include colorectal cancer, non-small cell lung cancer (NSCLC), pancreatic cancer, and other solid tumors.
The purpose of this study is to see how well avutometinib and defactinib work in people with thyroid cancer. The people in this study have one of these kinds of cancer:
Researchers are assessing a CAR T cell therapy to treat acute lymphoblastic leukemia (ALL) that keeps growing even with treatment. With CAR T cell therapy, some of your own T cells (a type of white blood cell) are removed. They are genetically modified (changed) in a lab to recognize your own cancer cells. The altered T cells, called CAR T cells, are then returned to your body to find and kill cancer cells. This treatment is a form of immunotherapy.
After a stem cell transplant, a condition called chronic graft-versus-host disease (cGVHD) can occur. The new donor immune cells (like T cells and B cells) attack the recipient's healthy tissues, thinking they are foreign. It usually starts around 100 days after the transplant, but it can begin earlier or later.
Researchers are doing this study to find out whether combining the standard chemotherapy for head and neck cancer with the immunotherapy drugs cetuximab and cemiplimab is a safe treatment. They also want to know if receiving this combination treatment before surgery may allow patients to forgo the standard radiation treatment given after surgery.
BNT326 is a type of drug called an antibody-drug conjugate (ADC). ADCs are made of a monoclonal antibody linked to a drug. The antibody binds to a protein on cancer cells called HER3, which plays a role in cancer cell growth. It then releases the anti-cancer drug to kill the cancer cell. By destroying these cells, BNT326 may help slow or stop the growth of your cancer. It is given intravenously (by vein).
Ibrutinib and rituximab are the standard treatment for Waldenström's macroglobulinemia (WM) and lymphoplasmacytic lymphoma (LL). In this study, researchers want to see if giving the medication venetoclax with the standard treatment is safe and more effective than the standard treatment alone in people with previously untreated WM/LL.
Prostate cancers initially need the male hormone testosterone for growth. Hormone therapies that lower the level of testosterone are among the best treatments for prostate cancers that have metastasized (spread). The benefits of hormone treatments often do not last, however. Over time, many prostate cancers keep growing even with hormonal therapies. These are called castration-resistant prostate cancers (CRPC).
